Dichlorohydroxyquinoline en es it fr

Dichlorohydroxyquinoline Brand names, Dichlorohydroxyquinoline Analogs

Dichlorohydroxyquinoline Brand Names Mixture

  • No information avaliable

Dichlorohydroxyquinoline Chemical_Formula


Dichlorohydroxyquinoline RX_link


Dichlorohydroxyquinoline fda sheet

Dichlorohydroxyquinoline msds (material safety sheet)

Dichlorohydroxyquinoline MSDS

Dichlorohydroxyquinoline Synthesis Reference

No information avaliable

Dichlorohydroxyquinoline Molecular Weight

1749.82 g/mol

Dichlorohydroxyquinoline Melting Point

No information avaliable

Dichlorohydroxyquinoline H2O Solubility


Dichlorohydroxyquinoline State


Dichlorohydroxyquinoline LogP

No information avaliable

Dichlorohydroxyquinoline Dosage Forms

Vials containing colistimethate sodium or pentasodium colistinmethanesulfonate (150 mg colistin base activity) for injection.

Dichlorohydroxyquinoline Indication

For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Dichlorohydroxyquinoline Pharmacology

Colistimethate is a polymyxin antibiotic agent. Originally, colistimethate sodium was thought to be less toxic than polymyxin B; however, if the drugs are administered at comparable doses, their toxicities may be similar. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.

Dichlorohydroxyquinoline Absorption

Very poor absorption from gastrointestinal tract.

Dichlorohydroxyquinoline side effects and Toxicity

Oral LD50 in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.

Dichlorohydroxyquinoline Patient Information

Dichlorohydroxyquinoline Organisms Affected

Gram-negative bacilli